Chemotherapy of experimental transitional-cell carcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Transitional-cell carcinoma of the bladder is a significant human cancer.
• Developing effective chemotherapy models is crucial for advancing treatment strategies.

Purpose of the Study:

• To evaluate the efficacy of various chemotherapeutic agents against a novel bladder carcinoma model.
• To establish a reliable animal model for studying bladder cancer chemotherapy.

Main Methods:

• Transitional-cell carcinoma was induced in C3H/He mice using N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT).
• The induced tumor was transplanted into syngeneic animals.
• The effectiveness of cyclophosphamide, cis-diammine dichloroplatinum (CACP), adriamycin, dactinomycin, mitomycin C, 5-fluorouracil, CCNU, BCNU, methotrexate, and hydroxyurea was evaluated.

Main Results:

• Cyclophosphamide and CACP significantly inhibited tumor growth and prolonged survival.
• Pre-treatment with cyclophosphamide prevented tumor growth entirely; post-treatment led to inhibition and a 45% cure rate.
• Combination chemotherapy with cyclophosphamide and CACP was more effective than single-agent therapy.
• Adriamycin, dactinomycin, and mitomycin C showed limited activity; 5-fluorouracil, CCNU, BCNU, methotrexate, and hydroxyurea were ineffective.

Conclusions:

• The FANFT-induced bladder tumor in mice is a suitable model for chemotherapy research due to its consistent growth and histological similarity to human bladder cancer.
• Cyclophosphamide and CACP show significant promise for bladder carcinoma treatment, with combination therapy offering enhanced efficacy.